The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.
Fierce Pharma Asia—Astellas' first-in-class FDA nod; Otsuka's IgAN win; Samsung Bio's $1.2B contract
Astellas' first-in-class CLDN18.2 drug Vyloy has cleared the FDA. After a positive phase 3 readout, Otsuka is targeting an ...
Vyloy is the first CLDN18.2-targeting drug to reach the US market but has already been approved in Japan as well as in the EU ...
The U.S. Food and Drug Administration has approved Vyloy (zolbetuximab-clzb) in combination with fluoropyrimidine- and ...
SurvivorNet on MSN3d
New FDA Approval: Vyloy (Zolbetuximab) — A Promising Option for Advanced Gastric CancerClaudin 18.2 testing is a crucial step in determining whether Vyloy will be an effective treatment option for you patients with advanced gastric cancer.
GlobalData on MSN4d
FDA approves Astellas’ VYLOY for gastric cancer treatmentAstellas Pharma has received approval from the FDA for VYLOY in conjunction with chemotherapy, for the treatment of advanced ...
The regulator’s approval on Friday of Vyloy for gastric or gastroesophageal junction cancer makes it the first and only ...
After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer ...
U.S. Food and Drug Administration (FDA) has approved VYLOY™ (zolbetuximab-clzb) in combination with fluoropyrimidine- and ...
Astellas Pharma today announced that the US Food and Drug Administration (FDA) has approved VYLOY (zolbetuximab-clzb) in ...
The US Food and Drug Administration has approved Vyloy (zolbetuximab-clzb), a claudin 18.2 (CLDN18.2)-directed cytolytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback